

**XXVIII Giuseppe Basso InterLab Meeting in Pediatric Hematology-Oncology
Padova (Falcade-Belluno) 24-25 giugno 2022**

PROGRAM

Venerdì 23-06-2022

14.00 Welcome Biffi-Buldini-Pigazzi

Oral communications:

14.10 Grazia Fazio (MZ): Summary di 6 mesi di trascrittoma in pazienti LAL alla diagnosi

14.30 Luigia Valsecchi (MZ): Role of the RNA binding protein MSI2 in infant ALL with MLL rearrangement

14.50 Caterina Tretti (PD): circRNA functional investigations in BCP-ALL with MLL::AF4 translocation

15.10 Francesca Gottardi (BO): Bcl2 expression and ex-vivo inhibition in pediatric HR-ALL: a correlation to in vivo Venetoclax treatment and clinical response

15.30 Thanos Oikonomou (MZ): Modeling target treatment in high-risk childhood ALL, focus in DS-ALL

15.50 Fabiola Guerra (MZ): Studio osservazionale prospettico e retrospettivo in pazienti adulti e pediatrici portatori di varianti di GATA2

16.15 Coffe break

16.50 Anna Tosato (PD): TRAP1: The Crossroad of Metabolic and Epigenetic Remodeling of B Cell Aggressive Lymphomas

17.10 Anna Garbin (PD): MiR-146a-5p is Enriched in Plasma Small Extracellular Vesicles of Pediatric ALCL Patients with Poor Prognosis and has a Role in Macrophage Polarization

17.30 Barbara Buldini (PD): "CD371-positive B-cell precursor ALL in childhood: an update from the iBFM Flow Network.

17.40 Giulia Gomiero (PD): Investigating the transcriptomic basis of switching B-cell Precursor Acute Lymphoblastic Leukemia

18.00 Giulia Veltri (PD): NFAT in T-ALL e GC resistance

18.20 Stefano Rebellato (MZ): Role of cohesin genes mutations in genetic predisposition to childhood hematological malignancies

18.40 Gianni Cazzaniga (MZ): Leucemia Linfoblastica Acuta Ipodiploide e sindrome di Li-Fraumeni

19.00 Chiusura lavori

19.30 Cena Sociale presso Hotel Belvedere Via Giuseppe Garibaldi, 28, 32020 Falcade Italia

Sabato 24/06/22

Oral communications

14.00 Giovanni Faggin (PD): CD72 is a pan-tumor antigen associated to pediatric acute leukemia”

14.20 Luca Persano (PD): Multi-omics characterization of chemotherapy-resistant models unveil targetable vulnerabilities in Medulloblastoma.

14.40 Lorenzo Manfreda (PD): Metabolic rewiring sustains chemotherapy resistance in medulloblastoma.

15.00 Denise Acunzo (MZ): Oncogene-induced senescence in *ETV6::RUNX1* pre-leukemia

15.20 Mayla Bertagna (MZ): *ETV6::RUNX1* pre-leukemic niche: role of infections and bone marrow microenvironment in leukemic onset

15.40 Giulia Borella (PD): Secret-OME in 3D AML bone marrow niche

16.00 Claudia Tregnago-Ambra Da Ros (PD): Drug screenings across AML models: 3D BM niche and PDXs

16.20 Salvatore Nicola Bertuccio (BO): Studio degli stadi precoci dell’ematopoiesi per identificare nuovi target terapeutici nelle non-DS-AMKL pediatriche

16.40 Silvia Bresolin (PD): Somatogenetic architecture in JMML:un update

17.00 Daria Messelodi (BO): Modeling delle alterazioni di CBL attraverso cellule staminali pluripotenti indotte

17.20 Maddalena Benetton (PD): New defining of LSCs in AML

17.40 Martina Pigazzi (PD): Role of Molecular MRD role in AIEOP-AML2013/01 protocol: a diagnostic update

18.30 chiusura lavori, saluti earrivederci al 17-18 Febbraio 2023.